Stem Cell Trial Nearly Approved

The first human trial of a treatment using induced pluripotent stem cells has received conditional approval from an institutional review board in Japan.

By | February 15, 2013

WIKIMEDIA, GTANNERMasayo Takahashi of the Center for Developmental Biology in Kobe, Japan, and colleagues are nearly ready to start using their experimental induced pluripotent stem (iPS) cell treatment in a human clinical trial, after receiving conditional approval from the institutional review board (IRB) at the Institute for Biomedical Research and Innovation (IBRI) on Wednesday (February 13)—the condition being the final results of ongoing preclinical safety studies. It will be the first human trial using an iPS cell treatment, Nature reported.

The therapy aims to treat age-related macular degeneration, a degenerative retinal condition that can cause blindness, by removing damaged epithelium and replacing it with new iPS cell-derived epithelium. Having already received IRB approval at her home institution, Takahashi is waiting for one of the last stages of approval—the final  by the health ministry—before the trial can begin. Takahashi and her colleagues hope to begin the trial, which will enroll 6 patients at least 50 years old, by March 2014.


Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Inside a Lab Mouse’s High-Fat Diet
  2. Battling the Bulge
    Bio Business Battling the Bulge

    Weight-loss drugs that target newly characterized obesity-related receptors and pathways could finally offer truly effective fat control.

  3. How Gastric Bypass Can Kill Sugar Cravings
  4. Birth of the Skin Microbiome
    Daily News Birth of the Skin Microbiome

    The immune system tolerates the colonization of commensal bacteria on the skin with the aid of regulatory T cells during the first few weeks of life, a mouse study shows.

Life Technologies